超过10年的非维生素K对抗剂口服抗凝剂:亮点,挑战和未来发展
Raffaele De Caterina1, Simona Chiusolo1
1Cardio-Thoracic and Vascular Department, Pisa University Hospital and University of Pisa, Via Paradisa, 2, 56125 Pisa, Italy.
概括
非维生素K抗剂的口服抗凝剂比较老的药物提供更安全,更方便的抗凝剂. 研究继续改进这些疗法,XI因子抑制剂显示出增强安全性的承诺.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 血液学 血液学 血液学
背景情况:
- 在过去的十年中,非维生素K对抗剂口服抗凝剂 (NOACs) 改变了抗凝疗法.
- 与维生素K对抗剂相比,NOACs提供了诸如降低出血风险,固定的剂量和更少的相互作用等优势.
- 它们在预防心房,静脉血栓栓塞和心血管疾病和癌症中的血栓形成中确立了它们的有效性.
研究的目的:
- 审查与NOACs相关的临床进展和挑战.
- 探索新兴的抗凝策略,特别是XI因子抑制剂.
主要方法:
- 本综述综合了当前临床数据和关于口服抗凝药疗法的研究成果.
- 它检查了该领域的好处,局限性和正在进行的发展.
主要成果:
- NOAC 显示出显著的好处,但仍然存在诸如出血风险和成本等挑战.
- 十一因子抑制剂被确定为潜在的下一代抗凝剂,具有更好的安全性.
结论:
- NOACs代表了抗凝固的重大改进,但需要进一步优化.
- 未来的研究,包括开发XI因子抑制剂,旨在提高抗凝治疗的安全性和有效性.
相关概念视频
Therapeutic Index
4.0K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
593
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
593
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
Coagulation
4.2K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.2K
Disorders of Hemostasis
680
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
680


